Company |
Type of |
Number of |
Amount |
Investors; placement agents; details |
Date |
TOTAL: $614.46M | |||||
4SC AG (Planegg-Martinsried, Germany) |
Private placement |
7.25S |
$31.69 |
4SC placed about 7.25M shares at €4 (US$4.18) each with existing shareholders in a rights issue and with selected new institutional investors in a subsequent rump placement, resulting in gross proceeds of €29M |
7/30/15 |
Abeona Therapeutics Inc. (New York) |
Warrant exercise |
N/A |
$4.6 |
Abeona Therapeutics received $4.6M through warrant exercises |
7/2/15 |
Abeona Therapeutics Inc. (New York) |
Private placement |
2.83S |
$15.5 |
Abeona raised $15.5M in a placement with Soros Fund Management and Perceptive Life Science Fund and two members of the board; the shares were sold at $5.50 each |
7/29/15 |
Ariad Pharmaceuticals Inc. (Cambridge, Mass.) |
Royalty sale |
N/A |
$200 |
Ariad agreed to pay mid-single-digit royalties on future sales of Iclusig (ponatinib) to PDL Biopharma in exchange for up to $200M in financing, including $50M at the deal's close and $50M a year from now on |
7/30/15 |
Cardiome Pharma Corp. (Vancouver, British Columbia) |
Bought deal financing |
2.5S |
$20 |
Cardiome Pharma is raising $20M in a bought deal financing, entering an agreement with a syndicate of underwriters led by Cormark Securities Inc., acting as sole bookrunner and co-lead underwriter, and Canaccord Genuity Corp., acting as co-lead, and including Brean Capital LLC and Laurentian Bank Securities, under which they agreed to purchase about 2.5M common shares priced at $8 each; Cardiome granted underwriters an overallotment option to purchase up to an additional 375,000 shares |
7/30/15 |
Cleveland Biolabs Inc. (Buffalo, N.Y.) |
Private placement |
6.5S |
$25 |
Cleveland Biolabs raised $25M through a placement of 6.5M shares at $3.87 each with venture investor David Davidovich |
7/10/15 |
CTD Holdings Inc. (Alachua, Fla.) |
Private placement |
2.6S |
$1.3 |
CTD Holdings closed a private placement, led by Novit L.P., by issuing 2.6M shares of common stock at $0.50 each |
7/14/15 |
Cynata Therapeutics Ltd. (Melbourne, Australia) |
Private placement of ordinary shares |
6.67S |
$3.7 |
Cynata issued 6.67M fully paid ordinary shares plus one attaching 13-month option for every two ordinary shares issued and one attaching five-year option for every two ordinary shares issued, to institutional investors in the U.S. in a private placement for aggregate gross proceeds of approximately A$5M (US$3.7M) |
7/16/15 |
Delmar Pharmaceuticals Inc. (Vancouver, British Columbia) |
Registered direct placement |
3.35S and 3.35W |
$2 |
Delmar accepted subscriptions from institutional and accredited investors for a registered direct placement of 3.35M shares of common stock and 3.35M common stock purchase warrants for aggregate purchases of $2M; each share was purchased at $0.60 a piece and each warrant entitles the holder to purchase an additional share of the company's common stock at $0.75 each for a period of five years |
7/28/15 |
Genspera Inc. (San Antonio) |
Private placement |
3.6S and W for 7.2S |
$2.5 |
Genspera entered definitive agreements with institutional investors, led by an undisclosed health care-dedicated fund, for a private placement of about 3.6M shares priced at 70 cents apiece and series D warrants to purchase an aggregate of about 3.6M shares at an exercise price of 80 cents each and series E warrants to purchase an aggregate of about 3.6M shares at an exercise price of 70 cents each, to raise $2.5M; H.C. Wainwright & Co. acted as the exclusive placement agent |
7/7/15 |
Immune Pharmaceuticals Inc. (New York) |
Term loan and private placement |
N/A |
$21.5 |
Immune Pharmaceuticals secured $21.5M, including $9.5M through a term loan from Hercules Technology Growth Capital Inc., and the placement of $12M in series D redeemable convertible preferred stock |
7/31/15 |
Medigene AG (Martinsried, Germany) |
Private placement |
5.6S |
$51.3 |
Medigene completed a capital increase of approximately €46.4M (US$51.3M) placing 5.6M newly offered shares, priced at €8.30 apiece; Baader Bank AG acted as sole global coordinator and bookrunner, with Trout Capital LLC as the U.S. selling agent |
7/2/15 |
Nantkwest Inc. (Cardiff-by-the-Sea, Calif.) |
Private placement |
0.68S |
$17 |
Nantkwest sold 680,000 shares in a private placement to Summit, N.J.-based Celgene Corp., an existing backer, at the $25 IPO price; it concurrently raised $207.5M in the IPO |
7/29/15 |
Neovacs SA (Paris) |
Private placement |
N/A |
$8.31 |
Neovacs closed a €7.5M (US$8.31M) share capital increase subscribed by U.S. institutional investors |
7/6/15 |
Novacyt (Paris) |
Private placement |
N/A |
$2.16 |
Novacyt completed a private placement of €2M (US$2.16M) with equity investors in the round receiving 399,500 new Novacyt shares |
7/21/15 |
Palatin Technologies Inc. (Cranbury, N.J.) |
Private placement and loan |
W for 24.09S |
$30 |
Palatin closed on a private placement of series E warrants to purchase 21.9M shares of its common stock and series F warrants to purchase 2.19M shares of its common stock; certain funds managed by QVT Financial LP invested $5M and another accredited investment fund invested $15M; the company also closed a $10M venture loan led by Horizon Technology Finance Corp. |
7/7/15 |
PDL Biopharma Inc. (Incline Village, Nev.) |
Debt financing |
N/A |
(up to $40) |
PDL Biopharma entered a credit agreement with Careview Communications Inc. to provide the firm with up to $40M of secured debt financing in two tranches of $20M |
7/1/15 |
Pharming Group NV (Leiden, the Netherlands) |
Debt financing |
N/A |
$17 |
Pharming Group entered a debt financing of €15.6M (US$17M) with Oxford Finance LLC and Silicon Valley Bank; the four-year promissory notes with the lenders carry a 7.02% fixed interest per annum |
7/21/15 |
Recro Pharma Inc. (Malvern, Pa.) |
Private placement |
1.4S |
$16 |
Recro Pharma entered into a definitive purchase agreement with institutional investors for a private placement of approximately 1.4M common shares priced at $11.60 apiece for gross proceeds of approximately $16M |
7/2/15 |
Reneuron plc (Guildford, UK) |
Private placement |
1.4S |
$106 |
Reneuron raised £68.4M (US$106M) through a placing of about 1.4M shares priced at 5 pence per share |
7/13/15 |
Resverlogix Corp. (Calgary, Alberta) |
Private placement |
13.3U |
$27 |
Resverlogix closed a private placement with Shenzhen Hepalink Pharmaceutical Co. Ltd., of Shenzhen, China, and Eastern Capital Ltd.; Hepalink subscribed for about 13.3M units, each comprising one common share and a fractional warrant for the purchase of additional shares, for aggregate proceeds of about C$35M (US$27M); each whole warrant is exercisable into one common share at C$2.67 per share for a period of five years |
7/22/15 |
Telesta Therapeutics Inc. (Montreal) |
Private placement |
ND |
$0.2 |
Telesta placed $200,000 in common shares with BL&H Co. Ltd., of Korea |
7/21/15 |
Txcell SA (Valbonne, France) |
Private placement |
N/A |
$8.7 |
Txcell completed a private placement of about €8M (US$8.7M) in shares; about 70% of the shares were placed internationally, outside France |
7/23/15 |
Xenetic Biosciences Inc. (Lexington, Mass.) |
Bridge note financing |
N/A |
$3 |
Xenetic completed a $3M bridge note financing with OJSC Pharmsynthez |
7/9/15 |
|
Notes This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed. Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. N/A = Not applicable; ND = Not disclosed. This chart includes only biotech companies that develop therapeutics. | |||||